Job title:
特任講師
Research theme for competitive and other funds (6):
2024 - 2027 T細胞抑制分子を標的とした新規がん免疫療法の開発
2021 - 2024 T細胞性免疫調整薬によるがんおよび抗ウイルス免疫療法の開発
2019 - 2022 Attempt of segmentation of positive / negative factor and absolute evaluation of intra-tumor immunity
2018 - 2021 Development of companion diagnostics for cancer immunotherapy
2015 - 2018 Development of Engager T cells for immunotherapy of lung cancer
2010 - 2011 Development of SOCS gene therapy for malignant pleural mesothelioma
Show all
Papers (64):
Yoshinori Hayashi, Azumi Ueyama, Soichiro Funaki, Koichi Jinushi, Naoko Higuchi, Hitomi Morihara, Michinari Hirata, Yoji Nagira, Takuro Saito, Atsunari Kawashima, et al. In situ analysis of CCR8+ regulatory T cells in lung cancer: suppression of GzmB+ CD8+ T cells and prognostic marker implications. BMC cancer. 2024. 24. 1. 627-627
Mari Tone, Kota Iwahori, Michinari Hirata, Azumi Ueyama, Akiyoshi Tani, Jun-Ichi Haruta, Yoshito Takeda, Yasushi Shintani, Atsushi Kumanogoh, Hisashi Wada. Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway. Journal for ImmunoTherapy of Cancer. 2024
Hanako Yoshimura, Yoshito Takeda, Yuya Shirai, Makoto Yamamoto, Daisuke Nakatsubo, Saori Amiya, Takatoshi Enomoto, Reina Hara, Yuichi Adachi, Ryuya Edahiro, et al. Galectin-10 in serum extracellular vesicles reflects asthma pathophysiology. The Journal of allergy and clinical immunology. 2024
Mari Tone, Kota Iwahori. PD-1 expression on tumor cells: a new target for cancer therapy. Translational lung cancer research. 2024. 13. 1. 186-189
Kota Iwahori, Takuro Nii, Norihiko Yamaguchi, Takahiro Kawasaki, Satomi Okamura, Kazuki Hashimoto, Takanori Matsuki, Kazuyuki Tsujino, Keisuke Miki, Akio Osa, et al. A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19. Scientific reports. 2023. 13. 1. 13809-13809